Antituberculosis Drug Research: A Critical Overview

Medicinal Research Reviews

Volumn 33, Issue 4, 2013, Pages 693-764

  Beena, ^a   Rawat, Diwan S ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

Ethambutol; H37Rv; Isoniazid; Multidrug resistant; Mycobacterium tuberculosis; PA824; SQ109; TMC207

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BCG VACCINE; BEDAQUILINE; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; DIAMINE; ENVIOMYCIN; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; NITROIMIDAZOLE; OXAZOLIDINONE DERIVATIVE; PROTIONAMIDE; PURINE; PYRAZINAMIDE; PYRIMIDINE; QUINOLINE; QUINOLONE; QUINOLONE DERIVATIVE; QUINONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; TERPENOID; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VIOMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL STRAIN; COLONY FORMING UNIT; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; DRUG TOLERABILITY; ENGELHARDIA ROXBURGHIANA; GROWTH INHIBITION; HUMAN; JUNIPERUS; MEDICINAL PLANT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SAPIUM HAEMATOSPERMUM; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; RESEARCH; TUBERCULOSIS;

EID: 84878639868     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21262     Document Type: Article

References (270)

1. Umesiri FE, Sanki AK, Boucau J, Ronning DR, Sucheck SJ. Recent advances toward the inhibition of mAG and LAM synthesis in Mycobacterium tuberculosis. Med Res Rev 2010;30:290-326.
2. Hardie RM, Watson JM. Mycobacterium bovis in England and Wales: Past, present and future. Epidemiol Infect 1992;109:23-33.
3. Nakajima C, Rahim Z, Fukushima Y, Sugawara I, van der Zanden AGM, Tamaru A, Suzuki Y. Identification of Mycobacterium tuberculosis clinical isolates in Bangladesh by a species distinguishable multiplex PCR. BMC Infect Dis 2010;10:118.
4. Waters WR, Palmer MV, Thacker TC, Davis WC, Sreevatsan S, Coussens P, Meade KG, Hope JC, Estes DM. Tuberculosis immunity: Opportunities from studies with cattle. Clin Dev Immunol 2011, doi:10.1155/2011/768542.
5. Dover LG, Coxon GD. Current status and research strategies in tuberculosis drug development. J Med Chem 2011;54:6157-6165.
6. Panteix G, Gutierrez MC, Boschiroli ML, Rouviere M, Plaidy A, Pressac D, Porcheret H, Chyderiotis G, Ponsada M, Van Oortegem K, Salloum S, Cabuzel S, Banuls AL, de Perre PV, Godreuil S. Pulmonary tuberculosis due to Mycobacterium microti: A study of six recent cases in France. J Med Microbiol 2010;59:984-989.
7. Sampaio EP, Elloumi HZ, Zelazny A, Ding L, Paulson ML, Sher A, Bafica AL, Shea YR, Holland SM. Mycobacterium abscessus and M. avium trigger toll-like receptor 2 and distinct cytokine response in human cells. Am J Resp Cell Mol Biol 2008;39:431-439.
8. Casal MM, Casal M. Immune response to mycobacteria. Curr Immunol Rev 2011;7:13-18.
9. Katoch VM. Newer diagnostic techniques for tuberculosis. Indian J Med Res 2004;120:418-428.
10. Munch R. Review: On the shoulders of giants. Microb Infect 2003;5:69-74.
11. Kaufmann SHE. A short history of Robert Koch's fight against tuberculosis: Those who do not remember the past are condemned to repeat it. Tuberculosis 2003;83:86-90.
12. Health topics. Tuberculosis. http://www.who.int/topics/tuberculosis/en/.
13. Rivers EC, Mancera RL. New antituberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov Today 2008;13:1090-1098.
14. World Health Organization 2010/2011 Tuberculosis Global Facts.
15. Goldman RC, Laughon BE. Discovery and validation of new antitubercular compounds as potential drug leads and probes. Tuberculosis 2009;89:331-333.
16. Kaufmann SHE, Parida SK. Tuberculosis in Africa: Learning from pathogenesis for biomarker identification. Cell Host Microb 2008;4:219-228.
17. Harper C. Tuberculosis, a neglected opportunity? Nat Med 2007;13:309-312.
18. Laughon BE. New tuberculosis drugs in development. Curr Topics Med Chem 2007;7:463-473.
19. Becerra MC, Bayona J, Freeman J, Farmer PE, Kim JY. Redefining MDR-TB transmission 'hot spots'. Int J Tuberc Lung Dis 2000;4:387-394.
20. Skeiky YAW, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006;4:469-476.
21. Rappuoli R, Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011;473:463-469.
22. Gordon SV, Pym AS. Genomics of the Mycobacterium tuberculosis complex. Handbook of Tuberculosis: Molecular Biology and Biochemistry. Weinheim: Wiley-VCH Verlag GmbH & Co.; 2008. p 193-211.
23. Ramon-Garcia S, Ng C, Anderson H, Chao JD, Zheng X, Pfeifer T, Av-Gay Y, Roberge M, Thompson CJ. Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. Antimicrob Agents Chemother 2011;55:3861-3869.
24. Ishikawa T. Benzo[c]phenanthridine bases and their antituberculosis activity. Med Res Rev 2001;21:61-72.
25. Tripathi RP, Tewari N, Dwivedi N, Tiwari VK. Fighting tuberculosis: An old disease with new challenges. Med Res Rev 2005;25:93-131.
26. Negi AS, Kumar JK, Luqman S, Saikia D, Khanuja SPS. Antitubercular potential of plants: A brief account of some important molecules. Med Res Rev 2010;30:603-645.
27. Almeida Da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: Classical and new drugs. J Antimicrob Chemother 2011;66:1417-1430.
28. Petroff SA, Branch A. Bacillus Calmette-Guerin (B.C.G.): Animal experimentation and prophylactic immunization of children. Am J Public Health 1928;18:843-864.
29. Zwerling A, Behr MA, Verma A, Brewer T, Menzies D, Pai M. The BCG World Atlas: A database of global BCG vaccination policies and practices. PLoS Med 2011;83:e1001012.
30. Barnesa PF, Samten B, Shams H, Vankayalapatib R. Progress in understanding the human immune responses to Mycobacterium tuberculosis. Tuberculosis 2009;89:S5-S9.
31. Barry PJ, O'Connor TM. Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem 2007;14:2000-2008.
32. Bernstein J, Lott WA, Steinberg BA, Yale HL. Chemotherapy of experimental tuberculosis. Am Rev Tuber 1952;65:357-364.
33. Fox HH. The chemical approach to the control of tuberculosis. Science 1952;116:129-134.
34. Yeager RL, Munroe WGC, Dessau FI. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am Rev Tuberc 1952;65:523-46.
35. Kushner S, Dalalian H, Sanjurjo JL, Bach FL, Safir SR, Jr., Smith VK, Jr., William JH. Experimental chemotherapy of tuberculosis: II. The synthesis of pyrazinamides and related compounds. J Am Chem Soc 1952;74:3617-3621.
36. Steele MA, Des Prez RM. The role of pyrazinamide in tuberculosis chemotherapy. Chest 1988;94:845-850.
37. Sheen P, Ferrer P, Gilman RH, Lopez-Llano J, Fuentes P, Valencia E, Zimic MJ. Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis 2009;89:109-113.
38. Sensi P. History of the development of rifampin. Rev Infect Dis 1983;5:S402-S406.
39. Hammam E, Beltagi AM, Ghoneim MM. Voltammetric assay of rifampicin and isoniazid drugs, separately and combined in bulk, pharmaceutical formulations and human serum at a carbon paste electrode. Microchem J 2004;77:53-62.
40. O'Brien RJ, Nunn PP. The need for new drugs against tuberculosis. Obstacles, opportunities and next steps. Am J Respir Crit Care Med 2001;163:1055-1058.
41. Dartois V, Barry CE. Clinical pharmacology and lesion penetrating properties of second-and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. Curr Clin Pharmacol 2010;5:96-114.
42. Murray CJ, DeJonghe E, Chum HJ, Nyangulu DS, Salomao A, Styblo K. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 1991;338:1305-1308.
43. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: International multicentre randomised trial. Lancet 2004;364:1244-1251.
44. Banerji D, Anderson S. A sociological study of awareness of symptoms among persons with pulmonary tuberculosis. Bull World Health Organ 1963;29:665-683.
45. Tyagi AK, Nangpal P, Satchidanandam V. Development of vaccines against tuberculosis. Tuberculosis 2011;91:469-478.
46. Espinal MA. The global situation of MDR-TB. Tuberculosis 2003;83:44-51.
47. Chiang CY, Enarson DA, Fujiwara PI, Van Deun A, Lee JJ. Strategies of extensively drug-resistant TB risk management for health workers and other care givers. Expert Rev Respir Med 2008;2:47-54.
48. Martins M, Viveiros M, Amaral L. The TB laboratory of the future: Macrophage-based selection of XDR-TB therapeutics. Future Microbiol 2008;3:135-144.
49. Denholm JT, McBryde ES. The use of antituberculosis therapy for latent TB infection. Infect Drug Resist 2010;3:63-72.
50. Ananthan S, Faaleolea ER, Goldman RC, Hobrath JV, Kwong CD, Laughon BE, Maddry JA, Mehta A, Rasmussen L, Reynolds RC, Secrist III JA, Shindo N, Showe DN, Sosa MI, Suling WJ, White EL. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis 2009;89:334-353.
51. WHO. Tuberculosis-fact sheet no. 104. Geneva 2000, 1-3.
52. Williams A, Hall Y, Orme IM. Evaluation of new vaccines for tuberculosis in the guinea pig model. Tuberculosis 2009;89:389-397.
53. Lead diamine antibiotic SQ109. 2011 http://www.sequella.com/docs/ExecutiveSummary
54. Chen P, Gearhart J, Protopopova M, Einck L, Nacy CA. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother 2006;58:332-337.
55. Jia L, Tomaszewski JE, Hanrahan C, Coward L, Noker P, Gorman G, Nikonenko B, Protopopova M. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 2005;144:80-87.
56. Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA. Drug therapy of experimental tuberculosis (TB): Improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 2007;51:1563-1565.
57. Spigelman MK. New tuberculosis therapeutics: A growing pipeline. J Infect Dis 2007;196:S28-S34.
58. Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. Safety, tolerability, and pharmacokinetics of PA824 in healthy subjects. Antimicrob Agents Chemother 2009;53:3720-3725.
59. Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grosset JH, Nuermberger EL. PA824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother 2011;55:239-245.
60. Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, Mthiyane TC, De Marez T, Heeswijk R, Kerstens R, Koul A, De Beule K, Donald PR, McNeeley DF. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52:2831-2835.
61. Dhillon J, Andries K, Phillips PPJ, Mitchison DA. Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis 2010;90:301-305.
62. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. OPC67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006;3:2131-2144.
63. Safety, efficacy and pharmacokinetics of OPC-67683 in patients with pulmonary tuberculosis. 2007 http://www.clinicaltrials.gov/ct/show/NCT00401271
64. A placebo-controlled, phase 2 trial to evaluate OPC 67683 in patients with pulmonary sputum culture-positive, multidrug-resistant tuberculosis (TB). 2011 http://clinicaltrials.gov/ct2/show/NCT00685360
65. Safety and pharmacokinetics (PK) in multidrug-resistant (MDR) refractive tuberculosis. 2011 http://clinicaltrials.gov/ct2/show/NCT01131351
66. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12:128-138.
67. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352-1361.
68. Anonymous. Tuberculosis. Scientific blueprint for TB drug development. Tuberculosis 2001;81:1-52.
69. Sirgel FA, Fourie PB, Donald PR, Nesri P, Roxana R, Jonathan L, Giorgio R, Jennifer N, Helen M, Denis MA. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005;172:128-135.
70. Mahamoud A, Chevalier J, Davin-Regli A, Barbe J, Pages JM. Quinoline derivatives as promising inhibitors of antibiotic efflux pump in multidrug resistant Enterobacter aerogenes isolates. Curr Drug Targets 2006;7:843-847.
71. Lilienkampf A, Mao J, Wan B, Wang Y, Franzblau SG, Kozikowski AP. Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis. J Med Chem 2009;52:2109-2118.
72. Denny WA, Wilson WR, Ware DC, Atwell GJ, Milbank JB, Stevenson RJ. Anti-cancer 2, 3-dihydro-1H-pyrrolo[3, 2-f]quinoline complexes of cobalt and chromium. U.S. Patent, 7064117, 2006.
73. Nasveld P, Kitchener S. Treatment of acute vivax malaria with tafenoquine. Trans R Soc Trop Med Hyg 2005;99:2-5.
74. Leatham PA, Bird HA, Wright V, Seymour D, Gordon A. A double blind study of antrafenine, naproxen and placebo in osteoarthrosis. Eur J Rheumatol Inflamm 1983;6:209-211.
75. Muruganantham N, Sivakumar R, Anbalagan N, Gunasekaran V, Leonard JT. Synthesis, anticonvulsant and antihypertensive activities of 8-substituted quinoline derivatives. Biol Pharm Bull 2004;27:1683-1687.
76. Maguire MP, Sheets KR, McVety K, Spada AP, Zilberstein A. A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem 1994;37:2129-2137.
77. Wilson WD, Zhao M, Patterson SE, Wydra RL, Janda L, Strekowski L, Schinazi RF. Design of RNA interactive anti-HIV-1 agents: Unfused aromatic intercalators. Med Chem Res 1992;2:102-110.
78. Strekowski L, Mokrosz JL, Honkan VA, Czarny A, Cegla MT, Patterson SE, Wydra RL, Schinazi RF. Synthesis and quantitative structure-activity relationship analysis of 2-(aryl or heteroaryl)quinolin-4-amines, a new class of anti-HIV-1 agents. J Med Chem 1991;34:1739-1746.
79. Andries K, Verhasselt P, Guillemont J, Goehlmann HWH, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-227.
80. Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, Ristic Z, Lill H, Dorange I, Guillemont J, Bald D, Andries K. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007;3:323-324.
81. Savini L, Chiasserini L, Gaeta A, Pellerano C. Synthesis and antitubercular evaluation of 4-quinolylhydrazones. Bioorg Med Chem 2002;10:2193-2198.
82. Gemma S, Savini L, Altarelli M, Tripaldi P, Chiasserini L, Coccone SS, Kumar V, Camodeca C, Campiani G, Novellino E, Clarizio S, Delogu G, Butini S. Development of antitubercular compounds based on a 4-quinolylhydrazone scaffold. Further structure-activity relationship studies. Bioorg Med Chem 2009;17:6063-6072.
83. Jain R, Vaitilingam B, Nayyar A, Palde PB. Substituted 4-methylquinolines as a new class of antituberculosis agents. Bioorg Med Chem Lett 2003;13:1051-1054.
84. Vangapandu S, Jain M, Jain R, Kaurb S, Singh PP. Ring-substituted quinolines as potential antituberculosis agents. Bioorg Med Chem 2004;12:2501-2508.
85. Vaitilingam B, Nayyar A, Palde PB, Monga V, Jain R, Kaur S, Singh PP. Synthesis and antimycobacterial activities of ring-substituted quinolinecarboxylic acid/ester analogues. Part 1. Bioorg Med Chem 2004;12:4179-4188.
86. Monga V, Nayyar A, Vaitilingam B, Palde PB, Jham S, Kaur S, Singh PP, Jain R. Ring-substituted quinolines. Part 2: Synthesis and antimycobacterial activities of ring-substituted quinolinecarbohydrazide and ring-substituted quinolinecarboxamide analogues. Bioorg Med Chem 2004;12:6465-6472
87. Candea ALP, Ferreira ML, Pais KC, Cardoso LNF, Kaiser CR, Henriques MGM, Lourenço MCS, Bezerra FAFM, de Souza MVN. Synthesis and antitubercular activity of 7-chloro-4-quinolinylhydrazones derivatives. Bioorg Med Chem Lett 2009;19:6272-6274.
88. Balamurugan K, Jeyachandran V, Perumal S, Manjashetty TH, Yogeeswari P, Sriram D. A microwave-assisted, facile, regioselective Friedländer synthesis and antitubercular evaluation of 2, 9-diaryl-2, 3-dihydrothieno-[3, 2-b]quinolines. Eur J Med Chem 2010;45:682-688.
89. De Souza MVN, Pais KC, Kaiser CR, Peralta MA, Ferreira ML, Lourenço MCS. Synthesis and in vitro antitubercular activity of a series of quinoline derivatives. Bioorg Med Chem 2009;17:1474-1480.
90. Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating M. tuberculosis. Antimicrob Agents Chemother 2007;51:1380-1385.
91. Mao J, Yuan H, Wang Y, Wan B, Pieroni M, Huang Q, Breemen RB, Kozikowski AP, Franzblau SG. From serendipity to rational antituberculosis drug discovery of mefloquine-isoxazole carboxylic acid esters. J Med Chem 2009;52:6966-6978.
92. Upadhayaya RS, Kulkarni GM, Vasireddy NR, Vandavasi JK, Dixit SS, Sharma V, Chattopadhyaya J. Design, synthesis and biological evaluation of novel triazole, urea and thiourea derivatives of quinoline against Mycobacterium tuberculosis. Bioorg Med Chem 2009;17:4681-4692.
93. Upadhayaya RS, Lahore SV, Sayyed AY, Dixit SS, Shinde PD, Chattopadhyaya J. Conformationally-constrained indeno[2, 1-c]quinolines. A new class of anti-mycobacterial agents. Org Biomol Chem 2010;8:2180-2197.
94. Nava-Zuazo C, Estrada-Soto S, Guerrero-Alvarez J, Leon-Rivera I, Molina-Salinas GM, Said-Fernandez S, Chan-Bacab MJ, Cedillo-Rivera R, Moo-Puc R, Miron-Lopez G, Navarrete-Vazquez G. Design, synthesis, and in vitro antiprotozoal, antimycobacterial activities of N-{2-[(7-chloroquinolin-4-yl)amino]ethyl}ureas. Bioorg Med Chem 2010;8:6398-6403.
95. Yang C, Tseng C, Chen Y, Lu C, Kao C, Wu M, Tzeng C. Identification of benzofuro[2, 3-b]quinoline derivatives as a new class of antituberculosis agents. Eur J Med Chem 2010;45:602-607.
96. Eswaran S, Adhikari AV, Pal NK, Chowdhury IH. Design and synthesis of some new quinoline-3-carbohydrazone derivatives as potential antimycobacterial agents. Bioorg Med Chem Lett 2010;20:1040-1044.
97. Ward P, Small L, Smith J, Suter P, Dutkowski R. Oseltamivir (tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005;55:i5-i21.
98. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 2008;453:1258-1262.
99. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Phan TV, Smythe ML, Whitem HF, Oliver SW, Colman PM, Varghese JN, Ryan DM, Woods JM, Bethell RC, Hotham VJ, Cameron JM, Penn CR. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993;363:418-423.
100. Woods JM, Bethell RC, Coates JAV, Healy N, Hiscox SA, Pearson BA, Ryan DM, Ticehurst J, Tilling J. 4-Guanidino-2, 4-dideoxy-2, 3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993;37:1473-1479.
101. Beggs WH, Andrews FA. Chemical characterization of ethambutol binding to Mycobacterium smegmatis. Antimicrob Agents Chemother 1974;5:234-239.
102. Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, Hamilton A, Mulkerin D, Graham M, Lockwood GF, Ivy P, Egorin M, Schuler B, Greenslade D, Goetz A, Knight R, Thomas R, Monahan BP, Dahut W, Grem JL. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function. J Clin Oncology 2003;21:2664-2672.
103. Zauli G, Rimondi E, Corallini F, Fadda R, Capitani S, Secchiero P. MDM2 antagonist nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway. J Bone Miner Res 2007;22:1621-1630.
104. De Souza AO, Hemerly FP, Busollo AC, Melo PS, Machado GMC, Miranda CC, Santa-Rita RM, Haun M, Leon LL, Sato DN, de Castro SL, Duran N. 3-[4′-Bromo-(1, 1′-biphenyl)-4-yl]-N, N-dimethyl-3-(2-thienyl)-2-propen-1-amine: synthesis, cytotoxicity, and leishmanicidal, trypanocidal and antimycobacterial activities. J Antimicrob Chemother 2002;50:629-637.
105. Kilburn JO, Greenberg J. Effect of ethambutol on the viable cell count in Mycobacterium smegmatis. Antimicrob Agents Chemother 1977;11:534-540.
106. Takayama K, Armstrong EL, Kunugi KA, Kilburn JO. Inhibition by ethambutol of mycolic acid transfer into the cell wall of Mycobacterium smegmatis. Antimicrob Agents Chemother 1979;16:240-242.
107. Kilburn JO, Takayama K. Effects of ethambutol on accumulation and secretion of trehalose mycolates and free mycolic acid in Mycobacterium smegmatis. Antimicrob Agents Chemother 1981;20:401-404.
108. Takayama K, Kilburn JO. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 1989;33:1493-1499.
109. Rozansky R, Bachrach U, Grossowicz N. Studies on the antibacterial action of spermine. J Gen Microbiol 1954;10:11-16.
110. Grange JM, Snell NJC. Activity of bromhexine and ambroxol, semi-synthetic derivatives of vasicine from the Indian shrub Adhatoda vasica, against Mycobacterium tuberculosis in vitro. J Ethnopharmacol 1996;50:49-53.
111. Lee RE, Protopopova M, Crooks E, Slayden RA, Terrot M, Barry CE III. Combinatorial lead optimization of [1, 2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem 2003;5:172-187.
112. Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J, Einck L, Nacy CA. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1, 2-ethylenediamines. J Antimicrob Chemother 2005;56:968-974.
113. Jia L, Noker PE, Coward L, Gorman GS, Protopopova M, Tomaszewski JE. Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol 2006;147:476-485.
114. Anonymous. SQ109. Tuberculosis 2008;88:159-161.
115. Lee RE, Mikusova K, Brennan PJ, Besra GS. Synthesis of the arabinose donor β-D-arabinofuranosyl-1-monophosphoryldecaprenol, development of a basic arabinosyl-transferase assay, and identification of ethambutol as an arabinosyl transferase Inhibitor. J Am Chem Soc 1995;117:11829-11832.
116. Shepherd RG, Baughn C, Cantrall ML, Goodstein B, Thomas JP, Wilkinson RG. Structure-activity studies leading to ethambutol, a new type of antituberculous compound. Ann NY Acad Sci 1966;135:686-710.
117. Bogatcheva E, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J, Barbosa F, Einck L, Nacy CA, Protopopova M. Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis. J Med Chem 2006;49:3045-3048.
118. Kelly BP, Furney SK, Jessen MT, Orme IM. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:2809-2812.
119. Onajole OK, Govender P, van Helden PD, Kruger HG, Maguire GEM, Wiid I, Govender T. Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates. Eur J Med Chem 2010;45:2075-2079.
120. Zhang X, Hu Y, Chen S, Luo R, Yue J, Zhang Y, Duan W, Wang H. Synthesis and evaluation of (S, S)-N, N′-bis-[3-(2, 2′, 6, 6′-tetramethylbenzhydryloxy)-2-hydroxypropyl]ethylenediamine (S2824) analogs with antituberculosis activity. Bioorg Med Chem Lett 2009;19:6074-6077.
121. Jia L, Tomaszewski JE, Noker PE, Gorman GS, Glaze E, Protopopova M. Simultaneous estimation of pharmacokinetic properties in mice of three antitubercular ethambutol analogs obtained from combinatorial lead optimization. J Pharm Biomed Anal 2005;37:793-799.
122. Razafimahefa D, Ralambomanana DA, Hammouche L, Pelinski L, Lauvagie S, Bebear C, Brocard J, Maugeind J. Synthesis and antimycobacterial activity of ferrocenyl ethambutol analogues and ferrocenyl diamines. Bioorg Med Chem Lett 2005;15:2301-2303.
123. Tripathi RP, Saxena N, Tiwari VK, Verma SS, Chaturvedi V, Manju YK, Srivastva AK, Gaikwad A, Sinha S. Synthesis and antitubercular activity of substituted phenylmethyl- and pyridylmethyl amines. Bioorg Med Chem 2006;14:8186-8196.
124. 2. Bioorg Med Chem Lett 2009;19:4937-4938.
125. Meng Q, Luo H, Chen Y, Wang T, Yao Q. Synthesis of novel [1, 2]-diamines with antituberculosis activity. Bioorg Med Chem Lett 2009;19:5372-5375.
126. del Olmo E, Molina-Salinas GM, Escarcena R, Alves M, Lopez-Perez JL, Hernandez-Pando R, Said-Fernandez S, San Feliciano A. Simple dihydrosphyngosine analogues with potent activity against MDR-Mycobacterium tuberculosis. Bioorg Med Chem Lett 2009;19:5764-5768.
127. Joshi MC, Bisht GS, Rawat DS. Syntheses and antibacterial activity of phendioxy substituted cyclic enediynes. Bioorg Med Chem Lett 2007;17:3226-3230.
128. Bisht GS, Rawat DS, Kumar A, Kumar R, Pasha S. Antimicrobial activity of rationally designed amino terminal modified peptides. Bioorg Med Chem Lett 2007;17:4343-4346.
129. Kumar N, Singh R, Rawat DS. Tetraoxanes: Synthetic and medicinal chemistry perspective. Med Res Rev. 2012;32:581-610.
130. Beena, Kumar N, Rohilla RK, Roy N, Rawat DS. Synthesis and antibacterial activity evaluation of metronidazole-triazole conjugates. Bioorg Med Chem Lett 2009;19:1396-1398.
131. Aggarwal N, Kumar R, Dureja P, Rawat DS. Schiff bases as potential fungicides and nitrification inhibitors. J Agric Food Chem 2009;57:8520-8525.
132. Joshi S, Bisht GS, Rawat DS, Kumar A, Kumar R, Maiti S, Pasha S. Interaction studies of novel cell selective antimicrobial peptides with model membranes and E. coli ATCC 11775. Biochim Biophys Acta 2010;1798:1864-1875.
133. Sharma M, Joshi P, Kumar N, Joshi S, Rohilla RK, Roy N, Rawat DS. Synthesis, antimicrobial activity and structure activity relationship study of N, N-dibenzyl-cyclohexane-1, 2-diamine derivatives. Eur J Med Chem 2011;46:480-487.
134. Kumar D, Joshi S, Rohilla RK, Roy N, Rawat DS. Synthesis and antibacterial activity of benzyl-[3-(benzylamino-methyl)-cyclohexylmethyl]-amine derivatives. Bioorg Med Chem Lett 2010;20:893-895.
135. Rawat DS, Sharma M, Roy N, Rohilla RK. Substituted cyclohexane-1, 2-diamine derivatives and related compounds as antimicrobial agents. Indian Patent Application No: 1462/DEL/2008.
136. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007;67:2077-2099.
137. Gootz TD, Brigthy KE. Chemistry and mechanism of action of the quinolone antibacterials. Quinolones (2nd edition). New York: Academic 1998. p 29-80.
138. Fass RJ. In vitro activity of bay 12-8039, a new 8-methoxyquinolone. Antimicrob Agents Chemother 1997;41:1818-1824.
139. Gootz TD, Brighty KE. Fluoroquinolone antibacterials: SAR, mechanism of action, resistance and clinical aspects. Med Res Rev 1996;16:433-486.
140. Gillespie SH, Morrissey I, Everett D. A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model. J Med Microbiol 2001;50:565-570.
141. Bartlett JG, Dowell SF, Mandell LA, File, Jr., TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347-382.
142. Huang ES, Stafford RS. National patterns in the treatment of urinary tract infections in women by ambulatory care physicians. Arch Intern Med 2002;162:41-47.
143. Lesher GY, Froelich EJ, Gruett MD, Bailey JH, Brundage RP. 1, 8-naphthyridine derivatives: A new class of chemotherapeutic agents. J Med Pharm Chem 1962;5:1063-1068.
144. Slade DA. A clinical trial of nalidixic acid (Negram, WIN.18, 320) in thirty-three patients with urinary infections treated in general practice. Br J Urol 1963;35:125-128.
145. Andriole VT. The future of the quinolones. Drugs 1993;45:1-7.
146. Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989;2:378-424.
147. Domagala JMJ. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994;33:685-706.
148. Jacobs MR. Fluoroquinolones as chemotherapeutics against mycobacterial infections. Current Pharm Des 2004;10:3213-3220.
149. Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 2001;61:9-18.
150. De Souza MVN, Vasconcelos TRA, de Almeida MV, Cardoso SH. Fluoroquinolones: An important class of antibiotics against tuberculosis. Curr Med Chem 2006;13:455-463.
151. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis and resistance. Lancet Infect Dis 2003;3:432-442.
152. Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: Past, present and future perspectives. Int J Antimicrob agents 2000;16:5-15.
153. Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H, Hobon DJ. A critical review of the fluoroquinolones: Focus on respiratory tract infections. Drugs 2002;62:13-59.
154. Andersson MI, MacGowan AP. Development of the quinolones. J Antimicrob Chemother 2003;51:1-11.
155. Boteva AA, Krasnykh OP. The methods of synthesis, modification and biological activity of 4-quinolones. Chem Heterocycl Compd 2009;45:757-785.
156. Ernst ME, Ernst EJ, Klepser ME. Levofloxacin and trovafloxacin: The next generation of fluoroquinolones? Am J Health Sys Pharm 1997;54:2569-2584.
157. Zhao YL, Chen YL, Sheu JY, Chen IL, Wang TC, Tzeng CC. Synthesis and antimycobacterial evaluation of certain fluoroquinolone derivatives. Bioorg Med Chem 2005;13:3921-3926.
158. Sriram D, Yogeeswari P, Basha JS, Radha DR, Nagaraja V. Synthesis and antimycobacterial evaluation of various 7-substituted ciprofloxacin derivatives. Bioorg Med Chem 2005;13:5774-5778
159. Sriram D, Aubry A, Yogeeswari P, Fisher LM. Gatifloxacin derivatives: Synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase. Bioorg Med Chem Lett 2006;16:2982-2985.
160. Aboul-Fadl T, Bin-Jubair FAS, Aboul-Wafa O. Schiff bases of indoline-2, 3-dione (isatin) derivatives and nalidixic acid carbohydrazide, synthesis, antitubercular activity and pharmacophoric model building. Eur J Med Chem 2010;45:4578-4586.
161. Carta A, Palomba M, Paglietti G, Molicotti P, Paglietti B, Cannas S, Zanetti S. [1, 2, 3]triazolo[4, 5-h]quinolones. A new class of potent antitubercular agents against multidrug resistant Mycobacterium tuberculosis strains. Bioorg Med Chem Lett 2007;17:4791-4794.
162. Carta A, Piras S, Palomba M, Jabes D, Molicotti P, Zanetti S. Antimycobacterial activity of quinolones. Triazoloquinolones as a new class of potent antimycobacterial agents. Anti-Infect Agents Med Chem 2008;7:134-147.
163. Shindikar AV, Viswanathan CL. Novel fluoroquinolones: Design, synthesis, and in vivo activity in mice against Mycobacterium tuberculosis H37Rv. Bioorg Med Chem Lett 2005;15:1803-1806.
164. Artico M, Mai A, Sbardella G, Massa S, Musiu C, Lostia S, Demontis F, Colla PL. Nitroquinolones with broad-spectrum antimycobacterial activity in vitro. Bioorg Med Chem Lett 1999;9:1651-1656.
165. O'Brien PJ. Molecular mechanisms of quinone cytotoxicity. Chem Biol Interact 1991;80:1-41.
166. Morton RA. Ed. Biochemistry of Quinones. New York: Academic Press; 1965. p 585.
167. Tran T, Saheba E, Arcerio AV, Chavez V, Li Q, Martinez LE, Primma TP. Quinones as antimycobacterial agents. Bioorg Med Chem 2004;12:4809-4813.
168. Komaraiah P, Ramakrishna SV, Reddanna P, Kavi Kishor PB. Enhanced production of plumbagin in immobilized cells of Plumbago rosea by elicitation and in situ adsorption. J Biotechnol 2003;101:181-187.
169. Satheeshkumar K, Seeni S. In vitro mass multiplication and production of roots in Plumbago rosea. Planta Med 2003;69:83-86.
170. Copp BR, Christiansen HC, Lindsay BS, Franzblau SG. Identification of heteroarylenamines as a new class of antituberculosis lead molecules. Bioorg Med Chem Lett 2005;15:4097-4099.
171. Wu C, Peng C, Tsai I, Abd El-Razek MH, Huang H, Chen I. Secondary metabolites from the roots of Engelhardia roxburghiana and their antitubercular activities. Phytochemistry 2007;68:1338-1343.
172. Mahapatra A, Mativandlela SPN, Binneman B, Fourie PB, Hamilton CJ, Meyer JJM, van der Kooy F, Houghtond P, Lalla N. Activity of 7-methyljuglone derivatives against Mycobacterium tuberculosis and as subversive substrates for mycothiol disulfide reductase. Bioorg Med Chem 2007;15:7638-7646.
173. Sturdy M, Krunic A, Cho S, Franzblau S, Orjala J. Eucapsitrione, an anti-Mycobacterium tuberculosis anthraquinone derivative from the cultured freshwater Cyanobacterium eucapsis sp. J Nat Prod 2010;73:1441-1443.
174. Collins L, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother 1997;41:1004-1009.
175. Trisuwan K, Khamthong N, Rukachaisirikul V, Phongpaichit S, Preedanon S, Sakayaroj J. Anthraquinone, cyclopentanone and naphthoquinone derivatives from the sea fan-derived fungi Fusarium spp. PSU-F14 and PSU-F135. J Nat Prod 2010;73:1507-1511.
176. Sommart U, Rukachaisirikul V, Sukpondma Y, Phongpaichit S, Sakayaroj J, Kirtikara K. Hydronaphthalenones and a dihydroramulosin from the endophytic fungus PSU-N24. Chem Pharm Bull 2008;56:1687-1690.
177. Sasaki H, Haraguchi Y, Itotani M, Kuroda H, Hashizume H, Tomishige T, Kawasaki M, Matsumoto M, Komatsu M, Tsubouchi H. Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2, 3-dihydroimidazo[2, 1-b]oxazoles. J Med Chem 2006;49:7854-7860.
178. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, Taylor K, Klein E, Manjunatha U, Gonzales J, Lee EG, Park SK, Raleigh JA, Cho SN, McMurray DN, Flynn JL, Barry CE III. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 2008;76: 2333-2640.
179. Boshoff HI, Barry CE III. Tuberculosis. Metabolism and respiration in the absence of growth. Nat Rev Microbiol 2005;3:70-80.
180. Barry CE, Boshoff HIM, Dowd CS. Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr Pharm Des 2004;10:3239-3262.
181. Dick T, Lee BH, Murugasu-Oei B. Oxygen depletion induced dormancy in Mycobacterium smegmatis. FEMS Microbiol Lett 1998;163:159-164.
182. Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994;38:2054-2058.
183. Agrawal KC, Bears KB, Sehgal RK, Brown JN, Rist PE, Rupp WD. Potential radiosensitizing agents. Dinitroimidazoles. J Med Chem 1979;22:583-586.
184. Nagarajan K, Shankar RG, Rajappa S, Shenoy SJ, Costa- Pereira R. Nitroimidazoles XXI 2, 3-dihydro-6-nitroimidazo[2, 1-b]oxazoles with antitubercular activity. Eur J Med Chem 1989;24:631-633.
185. Ashtekar DR, Costa-Perira R, Nagrajan K, Vishvanathan N, Bhatt AD, Rittel W. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1993;37:183-186.
186. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000;405:962-966.
187. New tuberculosis therapeutics: A growing pipeline. http://www.tballiance.org/newscenter/view-brief.php
188. Li X, Manjunatha UH, Goodwin MB, Knox JE, Lipinski CA, Keller TH, Barry CE III, Dowd CS. Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6, 7-dihydro-5H-imidazo[2, 1-b][1, 3]oxazines, analogues of PA824. Bioorg Med Chem Lett 2008;18:2256-2262.
189. Manjunatha UH, Boshoff H, Dowd CS, Zhang L, Albert TJ, Norton JE, Daniels L, Dick T, Pang SS, Barry CE III. Identification of a nitroimidazo-oxazine-specific protein involved in PA824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006;103:431-436.
190. Kim P, Zhang L, Manjunatha UH, Singh R, Patel S, Jiricek J, Keller TH, Boshoff HI, Barry CE III, Dowd CS. Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles. J Med Chem 2009;52:1317-1328.
191. Thompson AM, Blaser A, Anderson RF, Shinde SS, Franzblau SG, Ma Z, Denny WA, Palmer BD. Synthesis, reduction potentials and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6, 7-dihydro-5H-imidazo[2, 1-b][1, 3]oxazine (PA824). J Med Chem 2009;52:637-645.
192. Palmer BD, Thompson AM, Sutherland HS, Blaser A, Kmentova I, Franzblau SG, Wan B, Wang Y, Ma Z, Denny WA. Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6, 7-dihydro-5H-imidazo[2, 1-b][1, 3]oxazine (PA824). J Med Chem 2010;53:282-294.
193. Sutherland HS, Blaser A, Kmentova I, Franzblau SG, Wan B, Wang Y, Ma Z, Palmer BD, Denny WA, Thompson AM. Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chains. J Med Chem 2010;53:855-866.
194. Kmentova I, Sutherland HS, Palmer BD, Blaser A, Franzblau SG, Wan B, Wang Y, Ma Z, Denny WA, Thompson AM. Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6, 7-dihydro-5H-imidazo[2, 1-b][1, 3]oxazine (PA-824). J Med Chem 2010;53:8421-8439.
195. Thompson AM, Sutherland HS, Palmer BD, Kmentova I, Blaser A, Franzblau SG, Wan B, Wang Y, Ma Z, Denny WA. Synthesis and structure activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6, 7-dihydro-5H-imidazo-[2, 1-b][1, 3]oxazine (PA824). J Med Chem 2011;54:6563-6585.
196. Bollo S, Nunez-Vergara LJ, Kang S, Zhang L, Boshoff HI, Barry CE III, Squella JA, Dowd CS. The effect of 5-substitution on the electrochemical behaviour and antitubercular activity of PA824. Bioorg Med Chem Lett 2011;21:812-817.
197. Woldemichael GM, Gutierrez-Lugo M, Franzblau SG, Wang Y, Suarez E, Timmermann BN. Mycobacterium tuberculosis growth inhibition by constituents of Sapium haematospermum. J Nat Prod 2004;67:598-603.
198. Gordien AY, Gray AI, Franzblau SG, Seidel V. Antimycobacterial terpenoids from Juniperus communis L. (Cuppressaceae). J Ethnopharmcol 2009;126:500-505.
199. Singh S, Kumar JK, Saikia D, Shanker K, Thakur JP, Negi AS, Banerjee S. A bioactive labdane diterpenoid from Curcuma amada and its semisynthetic analogues as antitubercular agents. Eur J Med Chem 2010;45:4379-4382.
200. Molina-Salinas GM, Borquez J, Said-Fernandez S, Loyola LA, Yam-Puc A, Becerril-Montes P, Escalante-Erosa F, Pena-Rodriguez LM. Antituberculosis activity of alkylated mulinane diterpenoids. Fitoterapia 2010;81:219-222.
201. Molina-Salinas GM, Borquez J, Ardiles A, Said-Fernández S, Loyola LA, San-Martin A, Gonzalez-Collado I, Pena-Rodriguez LM. Antituberculosis activity of natural and semisynthetic azorellane and mulinane diterpenoids. Fitoterapia 2010;81:50-54.
202. Johnsson K, Schultz PG. Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis. J Am Chem Soc 1994;116:7425-7426.
203. Johnsson K, King DS, Schultz PG. Studies on the mechanism of action of isoniazid and ethionamide in the chemotherapy of tuberculosis. J Am Chem Soc 1995;117:5009-5010.
204. Marrakchi H, Laneelle G, Quemard A. InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. Microbiology 2000;146:289-296.
205. Fu LM, Shinnick TM. Understanding the action of INH on a highly INH-resistant Mycobacterium tuberculosis strain using genechips. Tuberculosis 2007;87:63-70.
206. Boruwa J, Kalita B, Barua NC, Borah JC, Mazumder S, Thakur D, Gogoib DK, Bora TC. Synthesis, absolute stereochemistry and molecular design of the new antifungal and antibacterial antibiotic produced by Streptomyces sp. 201. Bioorg Med Chem Lett 2004;14:3571-3574.
207. Sriram D, Yogeeswari P, Madhu K. Synthesis and in vitro and in vivo antimycobacterial activity of isonicotinoyl hydrazones. Bioorg Med Chem Lett 2005;15:4502-4505.
208. Lourenco MCD, Ferreira MD, de Souza MVN, Peralta MA, Vasconcelos TRA, Henriques MGMO. Synthesis and anti-mycobacterial activity of (E)-N'-(monosubstituted-benzylidene)isonicotinohydrazide derivatives. Eur J Med Chem 2008;43:1344-1347.
209. Slee AM, Wuanola MA, McRipley RJ, Zajac I, Zawada MJ, Bartolomew PT, Gregory WA, Forbes M. Oxazolidinones, a new class of synthetic antibacterial agents: In vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother 1987;31:1791-1797.
210. Brickner SJ, Hutchinson DK, Barbachyn MR, Manninen PR, Ulaniwicz DA, Garmon SA, Grega KC, Hendges SK, Toops DS, Ford CW, Zurenko GE. Synthesis and antibacterial activity of U100592 and U100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections. J Med Chem 1996;39:673-679.
211. Daly JS, Eliopoulos GM, Willey S, Moellering RC. Mechanism of action and in vitro and in vivo activities of S6123, a new oxazolidinone compound. Antimicrob Agents Chemother 1988;32:1341-1346.
212. Leach KL, Brickner SJ, Noe MC, Miller PF. Linezolid, the first oxazolidinone antibacterial agent. Ann NY Acad Sci 2011;1222:49-54.
213. Louie A, Liu W, Kulawy R, Drusano GL. In vivo pharmacodynamics of torezolid phosphate (TR701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother 2011;55:3453-3460.
214. Ashtekar DR, Costa-Periera R, Shrinivasan T, Iyyer R, Vishvanathan N, Rittel W. Oxazolidinones, a new class of synthetic antituberculosis agent in vitro and in vivo activities of DuP721 against Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 1991;14:465-471.
215. Brickner SJ. Oxazolidinone antibacterial agents. Curr Pharm Des 1996;2:175-194.
216. Barbachyn MR, Ford CW. Oxazolidinone structure-activity relationships leading to linezolid. Angew Chem Int Ed 2003;42:2010-2023.
217. Nilius AM. Have the oxazolidinones lived up to their billing? Future perspectives for this antibacterial class. Curr Opin Investig Drugs 2003;4:149-155.
218. Renslo AR, Luehr GW, Gordeev MF. Recent developments in the identification of novel oxazolidinone antibacterial agents. Bioorg Med Chem 2006;14:4227-4240.
219. Wilson DN, Schluenzen F, Harms JM, Starosta AL, Connell SR, Fucini P. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc Natl Acad Sci USA 2008;105:13339-13344.
220. Aoki H, Ke L, Poppe SM, Poel TJ, Weaver EA, Gadwood RC, Thomas RC, Shinabarger DL, Ganoza MC. Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes. Antimicrob Agents Chemother 2002;46:1080-1085.
221. Barbachyn MR, Hutchinson DK, Brickner SJ, Cynamon MH, Kilburn JO, Klemens SP, Glickman SE, Grega KC, Hendges SK, Toops DS, Ford CW, Zurenko GE. Identification of a novel oxazolidinone (U100480) with potent antimycobacterial activity. J Med Chem 1996;39:680-685.
222. Das B, Rudra S, Yadav A, Ray A, Raja Rao AVS, Srinivas ASSV, Soni A, Saini S, Shukla S, Pandya M, Bhateja P, Malhotra S, Mathur T, Arora SK, Rattan A, Mehta A. Synthesis and SAR of novel oxazolidinones: Discovery of ranbezolid. Bioorg Med Chem Lett 2005;15:4261-4267.
223. Sbardella G, Mai A, Artico M, Loddo R, Setzuc MG, Collac PL. Synthesis and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU100480. Bioorg Med Chem Lett 2004;14:1537-1541.
224. Dixit PP, Patil VJ, Nair PS, Jain S, Sinha N, Arora SK. Synthesis of 1-[3-(4-benzotriazol-1/2-yl-3-fluorophenyl)-2-oxo-oxazolidin-5-ylmethyl]-3-substituted-thiourea derivatives as antituberculosis agents. Eur J Med Chem 2006;41:423-428.
225. Kamal A, Shetti Rajesh VCRNC, Azeeza S, Swapna P, Khan MNA, Khan IA, Sharma S, Abdullah ST. Anti-tubercular agents. Part 6: Synthesis and antimycobacterial activity of novel arylsulfonamido conjugated oxazolidinones. Eur J Med Chem 2011;46:893-900.
226. Gangjee A, Yu J, Kisliuk RL, William H, Guilia S, McGuire JJ. Design, synthesis, and biological activities of classical N-{4-[2-(2-amino-4-ethylpyrrolo[2, 3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and as potential antitumor agents. J Med Chem 2003;46:591-600.
227. Ebrahim N, Zhou A, Khalili P, Leonard IW, Balzarini J, Erik DC, Edward EK. Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "Nitric oxide donor" Agents for evaluation as anticancer and antiviral agents. J Med Chem 2003;46:995-1004.
228. Morgan J, Haritakul R, Keller PA. Anilinopyrimidines as novel antituberculosis agents. Bioorg Med Chem Lett 2003;13:1755-1757.
229. Aponte JC, Vaisberg AJ, Castillo D, Gonzalez G, Estevez Y, Arevalo J, Quiliano M, Zimic M, Verastegui M, Malaga E, Gilman RH, Bustamante JM, Tarleton RL, Wang Y, Franzblau SG, Pauli GF, Sauvain M, Hammond GB. Trypanoside, anti-tuberculosis, leishmanicidal, and cytotoxic activities of tetrahydrobenzothienopyrimidines. Bioorg Med Chem 2010;18:2880-2886.
230. Pang RF, Zhang CL, Yuan DK, Yang M. Design and SAR of new substituted purines bearing aryl groups at N9 position as HIV-1 Tat-TAR interaction inhibitors. Bioorg Med Chem 2008;16:8178-8186.
231. Van Draanen NA, Freeman GA, Short SA, Harvey R, Jansen R, Szczech G, Koszalka GW. Synthesis and antiviral activity of 2'-deoxy-4'-thio purine nucleosides. J Med Chem 1996;39:538-542.
232. Parker WB, Long MC. Purine metabolism in Mycobacterium tuberculosis as a target for drug development. Curr Pharm Des 2007;13;599-608.
233. Andresen G, Gundersen L, Nissen-Meyer J, Rise F, Spilsberg B. Cytotoxic and antibacterial activity of 2-oxopurine derivatives. Bioorg Med Chem Lett 2002;12:567-569.
234. Pathak AK, Pathak V, Seitz LE, Suling WJ, Reynolds RC. Antimycobacterial agents. 1. Thio analogues of purine. J Med Chem 2004;47;273-276.
235. Skinner PS, Furney SK, Jacobs MR, Klopman G, Ellner JJ, Orme IM. A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions. Antimicrob Agents Chemother 1994;38:2557-2563.
236. Okachi R, Niino H, Kitaura K, Mineura K, Nakamizo Y, Murayama Y, Ono T, Nakamizo A. Synthesis and antibacterial activity of 2, 2'-dithiobis(benzamide) derivatives against Mycobacterium species. J Med Chem 1985;28:1772-1779.
237. Velezheva VS, Brennan PJ, Marshakov VY, Gusev DV, Lisichkina IN, Peregudov AS, Tchernousova LN, Smirnova TG, Andreevskaya SN, Medvedev AE. Novel pyridazino[4, 3-b]indoles with dual inhibitory activity against Mycobacterium tuberculosis and monoamine oxidase. J Med Chem 2004;47:3455-3461.
238. Huang Q, Mao J, Wan B, Wang Y, Brun R, Franzblau SG, Kozikowski AP. Searching for new cures for tuberculosis: Design, synthesis and biological evaluation of 2-methylbenzothiazoles. J Med Chem 2009;52:6757-6767.
239. Silva RSF, Pinto MCFR, Goulart MOF, de Souza Filho JD, Neves I, Jr., Lourenco MCS, Pinto AV. A macrolactone from benzo[a]phenazine with potent activity against Mycobacterium tuberculosis. Eur J Med Chem 2009;44:2334-2337.
240. Li X, Liu N, Zhang H, Knudson SE, Slayden RA, Tonge PJ. Synthesis and SAR studies of 1, 4-benzoxazine MenB inhibitors: Novel antibacterial agents against Mycobacterium tuberculosis. Bioorg Med Chem Lett 2010;20:6306-6309.
241. Trefzer C, Rengifo-Gonzalez M, Hinner MJ, Schneider P, Makarov V, Cole ST, Johnsson K. Benzothiazinones: Prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2′-epimerase DprE1 of Mycobacterium tuberculosis. J Am Chem Soc 2010;132:13663-13665.
242. Makarov V, Manina G, Mikusova K, Mollmann U, Ryabova O, Saint-Joanis B, Dhar N, Pasca MR, Buroni S, Lucarelli AP, Milano A, De Rossi E, Belanova M, Bobovska A, Dianiskova P, Kordulakova J, Sala C, Fullam E, Schneider P, McKinney JD, Brodin P, Christophe T, Waddell S, Butcher P, Albrethsen J, Rosenkrands I, Brosch R, Nandi V, Bharath S, Gaonkar S, Shandil RK, Balasubramanian V, Balganesh T, Tyagi S, Grosset J, Riccardi G, Cole ST. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 2009;324:801-804.
243. Pasca MR, Degiacomi G, de Jesus Lopes Ribeiro AL, Zara F, De Mori P, Heym B, Mirrione M, Brerra R, Pagani L, Pucillo L, Troupioti P, Makarov V, Cole ST, Riccardi G. Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. Antimicrob Agents Chemother 2010;54:1616-1618.
244. Kumar K, Awasthi D, Lee SY, Zanardi I, Ruzsicska B, Knudson S, Tonge PJ, Slayden RA, Ojima I. Novel trisubstituted benzimidazoles, targeting M. tb FtsZ, as a new class of antitubercular agents. J Med Chem 2011;54:374-381.
245. Dighe RD, Rohom SS, Dighe PD, Shiradkar MR. Condensed bridgehead nitrogen heterocyclic systems: Synthesis and evaluation of isatinyl thiazole derivatives as anti-Mycobacterium tuberculosis agents and dTDP-rhamnose inhibitors. Der Pharma Chemica 2011;3:418-432.
246. Torres E, Moreno E, Ancizu S, Barea C, Galiano S, Aldana I, Monge A, Perez-Silanes S. New 1, 4-di-N-oxide-quinoxaline-2-ylmethylene isonicotinic acid hydrazide derivatives as anti-Mycobacterium tuberculosis agents. Bioorg Med Chem Lett 2011;21:3699-3703.
247. Molnar J, Beladi I, Foldes I. Studies on the anti-tuberculotic action of some phenothiazine derivatives in vitro. Zentbl Bakteriol Parasitenkd Infektkrankh Hyg Abt 1 Orig 1977;239:521-526.
248. Kristiansen JE, Vergmann B. The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria. APMIS 1986;94:393-398.
249. Crowle AJ, Douvas GS, May MH. Chlorpromazine: A drug potentially useful for treating mycobacterial infections. Chemother 1992;38:410-419.
250. Kamisnka M. Role of chloropromazine in the treatment of pulmonary tuberculosis in psychiatric patients. Folia Medica Cracoviensia. 1967;9:115-143.
251. Bourdon JL. Contribution to the study of the antibiotic properties of chlorpromazine or 4560 RP. Ann Inst Pasteur 1961;101:876-886.
252. Bettencourt MV, Bosne-David S, Amaral L. Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis. Int J Antimicrob Agents 2000;16:69-71.
253. Ordway D, Viveiros M, Leandro C, Bettencourt R, Almeida J, Martins M, Kristiansen JE, Molnar J, Amaral L. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003;47:917-922.
254. van Soolingen D, Hernandez-Pando R, Orozco H, Aguilar D, Magis-Escurra C, Amaral L, van Ingen J, Boeree MJ. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One 2010;5:e12640.
255. Amaral L, Kristiansen JE, Abebe LS, Millet W. Inhibition of the respiration of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: Potential use for the initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother 1996;38:1049-1053.
256. Amaral L. It is anticipated that as is usually the case, financial motivation will move TZ from its current status "potential anti-MDR/XDR agent, " to one that will cure MDR and XDR TB. Recent Pat Antiinfect Drug Discov 2011;6:76.
257. Amaral L, Boeree MJ, Gillespie SH, Udwadia ZF, van Soolingen D. Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents 2010;35:524-526.
258. Amaral L, Kristiansen JE. Phenothiazines: an alternative to conventional therapy for the initial management of suspected multidrug resistant tuberculosis. A call for studies. Int J Antimicrob Agents 2000;14:173-176.
259. Reddy MV, Nadadhur G, Gangadharam PRJ. In-vitro and intracellular antimycobacterial activity of trifluoperazine. J Antimicrob Chemother 1996;37:196-197.
260. Ratnakar P, Murthy PS. Antitubercular activity of trifluoperazine, a calmodulin antagonist. FEMS Microbiol Lett 1992;97:73-76.
261. Yano T, Li LS, Weinstein E, Teh JS, Rubin H. Steady-state kinetics and inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2). J Biol Chem 2006;281:11456-11463.
262. Anonymous. Thioridazine. Tuberculosis 2008;88:164-167.
263. Amaral L, Viveiros M, Kristiansen JE. Phenothiazines: Potential alternatives for the management of antibiotic resistant infections of tuberculosis and malaria in developing countries. Trop Med Int Health 2001;6:1016-1022.
264. Amaral L, Kristiansen JE. Phenothiazines: Potential management of Creutzfeldt-Jacob disease and its variants. Int J Antimicrob Agents 2001;18:411-417.
265. Amaral L, Viveiros M, Kristiansen JE. Non-antibiotics: Alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. Curr Drug Targets 2006;7:887-891.
266. Martins M, Schelz Z, Martins A, Molnar J, Hajos G, Riedl Z, Viveiros M, Yalcin I, Aki-Sener E, Amaral L. The in vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis. Int J Antimicrob Agents 2007;29:338-340.
267. Amaral L, Martins M, Viveiros M. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J Antimicrob Chemother 2007;59:1237-1246.
268. Gadre DV, Talwar V. In vitro susceptibility testing of Mycobacterium tuberculosis strains to trifluoperazine. J Chemother 1999;11:203-206.
269. Chakrabarty AN, Bhattacharya CP, Dastidar SG. Antimycobacterial activity of methdilazine (Md), an antimicrobic phenothiazine. APIMS 1993;101:449-454.
270. Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, Laserson KF, Wells CD. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: A retrospective cohort study. Lancet 2005;365:318-326.